Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
NCT ID: NCT00261898
Last Updated: 2015-11-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
239 participants
Study Classification
INTERVENTIONAL
Study Start Date
2005-11-30
Study Completion Date
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
OBJECTIVE: Obesity and chronic sleep deprivation have both become increasingly pervasive medical problems in recent years. The prevalence of adult obesity has doubled over the past 30 years and continues to increase. In addition, industrial societies attach an economic value to maximizing the waking period to the longest tolerable limit by sleeping as little as possible. Average sleep time has decreased over the last century by 2 hours. Chronically sleeping less has been associated with increased weight, endocrine and metabolic health risks including glucose intolerance, cardiovascular disease, and mortality. The possibility that the current epidemic of obesity and metabolic health risks may be partially related to insufficient sleep is now being recognized. The objective of this proof-of-concept controlled trial is to investigate the impact of increasing sleep time in chronically sleep-deprived, obese subjects.
STUDY POPULATION: 18-50 year old, obese (BMI 30-50) men and premenopausal women, chronically sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep deprivation will be verified by the use of sleep logs and the use of actigraphy before entry into the study. Secondary causes of sleep deprivation such as insomnia, psychological (depression), and medical conditions associated with poor sleep quality (including obstructive sleep apnea) will be exclusionary criteria.
DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological fashion. The main analysis of the study will be to determine if additional sleep will result in a significant difference in body weight at the end of 12 months between the Intervention Group and the Comparison Group. In addition, we would like to establish whether 12 months of additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b) changes in the endocrine profile (i.e. inducing changes in leptin \[increase\] and ghrelin \[decrease\] opposite to the changes associated with chronic sleep deprivation). At the end of the 12-month intervention study (Phase 1, Efficacy Randomized Phase Study), all participants will be given information about the potential benefit of more sleep and encouraged to increase sleep time. Health teaching about proper nutrition and adequate exercise will also be provided at that time to the Intervention and Comparison Groups. All participants will be evaluated 6 months later to assess the effects of this intervention in a real-life situation, and offered participation in a three-year extension with semi-annual visits (Phase 2, Effectiveness 3 Year Follow-Up Phase Study), for which matched external comparison subjects will also be recruited ad hoc.
OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine and anthropometric measures, body composition, various metabolic parameters, food intake, energy expenditure, and quality of life measures.
STUDY POPULATION: 18-50 year old, obese (BMI 30-50) men and premenopausal women, chronically sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep deprivation will be verified by the use of sleep logs and the use of actigraphy before entry into the study. Secondary causes of sleep deprivation such as insomnia, psychological (depression), and medical conditions associated with poor sleep quality (including obstructive sleep apnea) will be exclusionary criteria.
DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological fashion. The main analysis of the study will be to determine if additional sleep will result in a significant difference in body weight at the end of 12 months between the Intervention Group and the Comparison Group. In addition, we would like to establish whether 12 months of additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b) changes in the endocrine profile (i.e. inducing changes in leptin \[increase\] and ghrelin \[decrease\] opposite to the changes associated with chronic sleep deprivation). At the end of the 12-month intervention study (Phase 1, Efficacy Randomized Phase Study), all participants will be given information about the potential benefit of more sleep and encouraged to increase sleep time. Health teaching about proper nutrition and adequate exercise will also be provided at that time to the Intervention and Comparison Groups. All participants will be evaluated 6 months later to assess the effects of this intervention in a real-life situation, and offered participation in a three-year extension with semi-annual visits (Phase 2, Effectiveness 3 Year Follow-Up Phase Study), for which matched external comparison subjects will also be recruited ad hoc.
OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine and anthropometric measures, body composition, various metabolic parameters, food intake, energy expenditure, and quality of life measures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
NCT02171273
Aging
Sleep Restriction
Circadian Disruption
COMPLETED
NA
Home Sleep and Metabolism
NCT02253368
Overweight
Sleep
COMPLETED
NA
The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism
NCT01800253
Sleep Deprivation
Sleep
COMPLETED
NA
Sleep Deprivation and Energy Balance
NCT01334788
Sleep Deprivation
COMPLETED
NA
Metabolic Effects of Sleep Extension in People With Obesity
NCT03594994
Insulin Resistance
Obesity
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVE: Obesity and chronic sleep deprivation have both become increasingly pervasive medical problems in recent years. The prevalence of adult obesity has doubled over the past 30 years and continues to increase. In addition, industrial societies attach an economic value to maximizing the waking period to the longest tolerable limit by sleeping as little as possible. Average sleep time has decreased over the last century by 2 hours. Chronically sleeping less has been associated with increased weight, endocrine and metabolic health risks including glucose intolerance, cardiovascular disease, and mortality. The possibility that the current epidemic of obesity and metabolic health risks may be partially related to insufficient sleep is now being recognized. The objective of this proof-of-concept controlled trial is to investigate the impact of increasing sleep time in chronically sleep-deprived, obese subjects.
STUDY POPULATION: 18-50 year old, obese (BMI 29-55) men and premenopausal women, chronically sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep deprivation will be verified by the use of sleep logs and the use of actigraphy before entry into the study. Secondary causes of sleep deprivation such as insomnia, psychological (depression), and medical conditions associated with poor sleep quality (including obstructive sleep apnea) will be exclusionary criteria.
DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological fashion. The main analysis of the study will be to determine if additional sleep will result in a significant difference in body weight at the end of 12 months between the Intervention Group and the Comparison Group. In addition, we would like to establish whether 12 months of additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b) changes in the endocrine profile (i.e. inducing changes in leptin \[increase\] and ghrelin \[decrease\] opposite to the changes associated with chronic sleep deprivation). At the end of the 12-month intervention study (Phase 1, Efficacy \[Randomized Phase\] Study), all participants will be given information about the potential benefit of more sleep and encouraged to increase sleep time. Health teaching about proper nutrition and adequate exercise will also be provided at that time to the Intervention and Comparison Groups. All participants will be evaluated 6 months later to assess the effects of this intervention in a real-life situation, and offered participation in a three-year extension with semi-annual visits (Phase 2, Effectiveness \[3 Year Follow-Up Phase\] Study), for which matched external comparison subjects will also be recruited ad hoc.
OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine and anthropometric measures, body composition, various metabolic parameters, food intake, energy expenditure, and quality of life measures.
The study was terminated early for reasons of apparent futility of continuing accrual of participants according to the original study plan. The decision was based on independent analysis of data acquired during the initial feasibility phase and from interim analysis of early results that failed to document objectively the achievement of substantive and meaningful differences between experimental and control groups with respect to amounts of sleep extension, changes in metabolic parameters, or changes in weight. Feasibilities of achieving objective and substantive differences in these parameters were integral to the methodology of the original study plan and required to meet the statistical power calculations for the controlled trial.
STUDY POPULATION: 18-50 year old, obese (BMI 29-55) men and premenopausal women, chronically sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep deprivation will be verified by the use of sleep logs and the use of actigraphy before entry into the study. Secondary causes of sleep deprivation such as insomnia, psychological (depression), and medical conditions associated with poor sleep quality (including obstructive sleep apnea) will be exclusionary criteria.
DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological fashion. The main analysis of the study will be to determine if additional sleep will result in a significant difference in body weight at the end of 12 months between the Intervention Group and the Comparison Group. In addition, we would like to establish whether 12 months of additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b) changes in the endocrine profile (i.e. inducing changes in leptin \[increase\] and ghrelin \[decrease\] opposite to the changes associated with chronic sleep deprivation). At the end of the 12-month intervention study (Phase 1, Efficacy \[Randomized Phase\] Study), all participants will be given information about the potential benefit of more sleep and encouraged to increase sleep time. Health teaching about proper nutrition and adequate exercise will also be provided at that time to the Intervention and Comparison Groups. All participants will be evaluated 6 months later to assess the effects of this intervention in a real-life situation, and offered participation in a three-year extension with semi-annual visits (Phase 2, Effectiveness \[3 Year Follow-Up Phase\] Study), for which matched external comparison subjects will also be recruited ad hoc.
OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine and anthropometric measures, body composition, various metabolic parameters, food intake, energy expenditure, and quality of life measures.
The study was terminated early for reasons of apparent futility of continuing accrual of participants according to the original study plan. The decision was based on independent analysis of data acquired during the initial feasibility phase and from interim analysis of early results that failed to document objectively the achievement of substantive and meaningful differences between experimental and control groups with respect to amounts of sleep extension, changes in metabolic parameters, or changes in weight. Feasibilities of achieving objective and substantive differences in these parameters were integral to the methodology of the original study plan and required to meet the statistical power calculations for the controlled trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Obesity
Chronic Sleep Deprivation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Primary Study Purpose
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Increase sleep
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 to 50 year old obese men and premenopausal women
BMI between 29-55
Chronically (for more than 6 months) sleep-deprived, defined as sleeping on a regular basis less than or equal to approximately 6-1/2 hours/night by history and objective devices (wrist activity monitors and sleep logs).
BMI between 29-55
Chronically (for more than 6 months) sleep-deprived, defined as sleeping on a regular basis less than or equal to approximately 6-1/2 hours/night by history and objective devices (wrist activity monitors and sleep logs).
Exclusion Criteria
Diagnosed sleep disorders including:
* Chronic insomnia
* Untreated sleep disordered breathing (sleep apnea at a level of severity \[using standardized criteria for measurement\], or diagnosed UARS \[upper airway resistance syndrome\] that would impair the ability to increase sleep duration \[Intervention Group\] or maintain sleep duration \[Comparison Group\]. CPAP treatment that has been in place for 3 months or more and improves sleep is acceptable).
* Restless leg syndrome or periodic limb movement disorder
* Parasomnias (including REM sleep behavior disorders, confusional arousals, sleep terrors, sleepwalking, sleep violence)
* Primary bruxism is allowed as long as it does not interfere with the ability to sleep an additional 90 minutes a night
* Narcolepsy
* Central apnea.
Unstable weight (voluntary losses in BMI greater than 5% over the past 6 months); currently being enrolled in a weight loss program
Untreated or uncontrolled diabetes
Severe uncontrolled hypertension
Other chronic organ disease diagnosis including:
* COPD
* Chronic cardiac arrhythmia requiring treatments
* Gastro-esophageal disorders associated with sleep-related symptoms.
Medications
* chronic use of prescription or over-the-counter medications known to affect sleep (e.g., systemic steroids, NSAIDs)
* current anticonvulsant therapy
Chronic fatigue syndrome and fibromyalgia
Acromegaly, hypothyroidism (unless on a stable replacement dose of thyroid hormone), Cushing disease or other endocrine disorders known to affect sleep
Poorly controlled major depression (subjects who have been on a stable pharmacological antidepressant treatment for 3 months and are in remission without substantial weight gain are eligible).
Other current DSM-IV diagnoses, including:
* Eating disorders such as bulimia nervosa and binge eating disorder
* Anxiety disorders such as PTSD and panic attacks
* Mania
* Schizophrenia.
Medication and substance abuse such as excessive alcohol consumption or drug abuse or dependence that may pose a threat to compliance
Being a rotating worker, shift worker (working evenings or nights), or long distance commuter (more than approximately 90 minutes each way), traveling frequently outside of time zone; being in an occupation that may require special vigilance such as driving a truck, bus, or cab; operating heavy machinery; being a pilot or air traffic controller
Being likely to move to a different geographical area during the study
Having a sleep partner that would make compliance with study requirements difficult
Pregnancy and lactation
Menopause
Chronic excessive caffeine use (habitual intake of more than 500 mg/day)
Any condition that in the opinion of the principal investigator makes study participation and compliance problematic.
* Chronic insomnia
* Untreated sleep disordered breathing (sleep apnea at a level of severity \[using standardized criteria for measurement\], or diagnosed UARS \[upper airway resistance syndrome\] that would impair the ability to increase sleep duration \[Intervention Group\] or maintain sleep duration \[Comparison Group\]. CPAP treatment that has been in place for 3 months or more and improves sleep is acceptable).
* Restless leg syndrome or periodic limb movement disorder
* Parasomnias (including REM sleep behavior disorders, confusional arousals, sleep terrors, sleepwalking, sleep violence)
* Primary bruxism is allowed as long as it does not interfere with the ability to sleep an additional 90 minutes a night
* Narcolepsy
* Central apnea.
Unstable weight (voluntary losses in BMI greater than 5% over the past 6 months); currently being enrolled in a weight loss program
Untreated or uncontrolled diabetes
Severe uncontrolled hypertension
Other chronic organ disease diagnosis including:
* COPD
* Chronic cardiac arrhythmia requiring treatments
* Gastro-esophageal disorders associated with sleep-related symptoms.
Medications
* chronic use of prescription or over-the-counter medications known to affect sleep (e.g., systemic steroids, NSAIDs)
* current anticonvulsant therapy
Chronic fatigue syndrome and fibromyalgia
Acromegaly, hypothyroidism (unless on a stable replacement dose of thyroid hormone), Cushing disease or other endocrine disorders known to affect sleep
Poorly controlled major depression (subjects who have been on a stable pharmacological antidepressant treatment for 3 months and are in remission without substantial weight gain are eligible).
Other current DSM-IV diagnoses, including:
* Eating disorders such as bulimia nervosa and binge eating disorder
* Anxiety disorders such as PTSD and panic attacks
* Mania
* Schizophrenia.
Medication and substance abuse such as excessive alcohol consumption or drug abuse or dependence that may pose a threat to compliance
Being a rotating worker, shift worker (working evenings or nights), or long distance commuter (more than approximately 90 minutes each way), traveling frequently outside of time zone; being in an occupation that may require special vigilance such as driving a truck, bus, or cab; operating heavy machinery; being a pilot or air traffic controller
Being likely to move to a different geographical area during the study
Having a sleep partner that would make compliance with study requirements difficult
Pregnancy and lactation
Menopause
Chronic excessive caffeine use (habitual intake of more than 500 mg/day)
Any condition that in the opinion of the principal investigator makes study participation and compliance problematic.
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
lead
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giovanni Cizza, M.D.
Role: PRINCIPAL_INVESTIGATOR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Cizza G, Skarulis M, Mignot E. A link between short sleep and obesity: building the evidence for causation. Sleep. 2005 Oct;28(10):1217-20. doi: 10.1093/sleep/28.10.1217. No abstract available.
Reference Type
BACKGROUND
Cizza G, Romagni P, Lotsikas A, Lam G, Rosenthal NE, Chrousos GP. Plasma leptin in men and women with seasonal affective disorder and in healthy matched controls. Horm Metab Res. 2005 Jan;37(1):45-8. doi: 10.1055/s-2005-861033.
Reference Type
BACKGROUND
Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004 Jun;89(6):2583-9. doi: 10.1210/jc.2004-0535.
Reference Type
BACKGROUND
Gangwisch JE, Malaspina D, Boden-Albala B, Heymsfield SB. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep. 2005 Oct;28(10):1289-96. doi: 10.1093/sleep/28.10.1289.
Reference Type
BACKGROUND
Hasler G, Buysse DJ, Klaghofer R, Gamma A, Ajdacic V, Eich D, Rossler W, Angst J. The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep. 2004 Jun 15;27(4):661-6. doi: 10.1093/sleep/27.4.661.
Reference Type
BACKGROUND
Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004 Dec 7;141(11):846-50. doi: 10.7326/0003-4819-141-11-200412070-00008.
Reference Type
BACKGROUND
Wehr TA. Effect of seasonal changes in daylength on human neuroendocrine function. Horm Res. 1998;49(3-4):118-24. doi: 10.1159/000023157.
Reference Type
BACKGROUND
Cizza G, Piaggi P, Rother KI, Csako G; Sleep Extension Study Group. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One. 2014 Aug 20;9(8):e104176. doi: 10.1371/journal.pone.0104176. eCollection 2014.
Reference Type
BACKGROUND
Cizza G, Marincola P, Mattingly M, Williams L, Mitler M, Skarulis M, Csako G. Treatment of obesity with extension of sleep duration: a randomized, prospective, controlled trial. Clin Trials. 2010 Jun;7(3):274-85. doi: 10.1177/1740774510368298. Epub 2010 Apr 27.
Reference Type
BACKGROUND
Lucassen EA, Piaggi P, Dsurney J, de Jonge L, Zhao XC, Mattingly MS, Ramer A, Gershengorn J, Csako G, Cizza G; Sleep Extension Study Group. Sleep extension improves neurocognitive functions in chronically sleep-deprived obese individuals. PLoS One. 2014 Jan 15;9(1):e84832. doi: 10.1371/journal.pone.0084832. eCollection 2014.
Reference Type
DERIVED
Cizza G, Piaggi P, Lucassen EA, de Jonge L, Walter M, Mattingly MS, Kalish H, Csako G, Rother KI; Sleep Extension Study Group. Obstructive sleep apnea is a predictor of abnormal glucose metabolism in chronically sleep deprived obese adults. PLoS One. 2013 May 29;8(5):e65400. doi: 10.1371/journal.pone.0065400. Print 2013.
Reference Type
DERIVED
Lucassen EA, Zhao X, Rother KI, Mattingly MS, Courville AB, de Jonge L, Csako G, Cizza G; Sleep Extension Study Group. Evening chronotype is associated with changes in eating behavior, more sleep apnea, and increased stress hormones in short sleeping obese individuals. PLoS One. 2013;8(3):e56519. doi: 10.1371/journal.pone.0056519. Epub 2013 Mar 6.
Reference Type
DERIVED
de Jonge L, Zhao X, Mattingly MS, Zuber SM, Piaggi P, Csako G, Cizza G; NIDDK Sleep Extension Study Group. Poor sleep quality and sleep apnea are associated with higher resting energy expenditure in obese individuals with short sleep duration. J Clin Endocrinol Metab. 2012 Aug;97(8):2881-9. doi: 10.1210/jc.2011-2858. Epub 2012 Jun 11.
Reference Type
DERIVED
Knutson KL, Galli G, Zhao X, Mattingly M, Cizza G; NIDDK Sleep Extension Study. No association between leptin levels and sleep duration or quality in obese adults. Obesity (Silver Spring). 2011 Dec;19(12):2433-5. doi: 10.1038/oby.2011.248. Epub 2011 Jul 28.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-DK-0036
Identifier Type: -
Identifier Source: secondary_id
060036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Sleep Restriction and Obesity
NCT01580761
COMPLETED
NA
Effect of Sleep Extension on Ceramides in People with Overweight and Obesity
NCT06180837
RECRUITING
NA
Sleep Extension or Regularity to Reduce Diabetes Risk
NCT06128265
COMPLETED
NA
Effects of Chronic Sleep Restriction in Young and Older People
NCT00506428
UNKNOWN
NA
Sleep Disturbances as a Risk Factor in Chronic Kidney Disease
NCT00817427
COMPLETED
NA
Sleep and Social Experiences Study 2
NCT05166590
COMPLETED
NA
A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation
NCT00123214
COMPLETED
NA
Social Determinants of Sleep and Obesity
NCT05698693
RECRUITING
EARLY_PHASE1
Metabolic and Cognitive Parameters Following Partial Sleep Deprivation
NCT01823263
UNKNOWN
NA
Effects of Sleep Deprivation on Food Intake and Motor Activity in Man
NCT00986492
COMPLETED
Impact of a Sleep Debt in Middle-Aged and Older Adults
NCT00817700
COMPLETED
NA
Validation and Exploration of Sleep and Mood Predictors
NCT00005401
COMPLETED
Effects of Time of Sleep Restriction in Obesity
NCT01259895
COMPLETED
The Impact of Sleep Restriction on Gastric Emptying, Appetite and Energy Intake
NCT05953285
RECRUITING
NA
Impact of Sleep Restriction in Women
NCT02835261
COMPLETED
NA
Study of Disrupted Sleep in Somali Americans
NCT05411029
RECRUITING
Mechanisms of Sleep Disruption Hyperalgesia
NCT01794689
COMPLETED
NA
Sleep and Metabolism
NCT05775627
RECRUITING
NA
Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes.
NCT00724087
COMPLETED
NA
Sleep Timing and Insulin Resistance in Adolescents With Obesity
NCT02585830
COMPLETED
Short Term Effects of Increasing Sleep Duration
NCT01428687
COMPLETED
PHASE2
P20 Extending Sleep to Reverse Metabolic Syndrome
NCT03596983
COMPLETED
NA
Sleep Deprivation and Energy Balance
NCT00935402
COMPLETED
NA
Menopausal Sleep Fragmentation and Body Fat Gain
NCT03047330
COMPLETED
PHASE4
Cardiometabolic Risk of Shiftwork
NCT01264913
TERMINATED